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Understanding Dengue Virus 
Capsid Protein Interaction with 
Key Biological Targets
André F. Faustino1,*, Ivo C. Martins1,*, Filomena A. Carvalho1, Miguel A. R. B. Castanho1, 
Sebastian Maurer-Stroh2,3 & Nuno C. Santos1
Dengue virus (DENV) causes over 500,000 hospitalizations and 20,000 deaths worldwide every 
year. Dengue epidemics now reach temperate regions due to globalization of trade and travel 
and climate changes. Currently, there are no successful therapeutic or preventive approaches. We 
previously developed a peptide drug lead, pep14-23, that inhibits the biologically relevant interaction 
of DENV capsid (C) protein with lipid droplets (LDs). Surprisingly, pep14-23 also inhibits DENV C 
interaction with very low-density lipoproteins (VLDL). We thus investigated the similarity between 
the proposed DENV C molecular targets in LDs and VLDL, respectively, the proteins perilipin 3 
(PLIN3) and apolipoprotein E (APOE). APOE N-terminal and PLIN3 C-terminal regions are remarkably 
similar, namely APOE α -helix 4 (APOEα 4) and PLIN3 α -helix 5 (PLIN3α 5) sequences, which are 
also highly superimposable structurally. Interestingly, APOE α -helical N-terminal sequence and 
structure superimposes with DENV C α -helices α 1 and α 2. Moreover, the DENV C hydrophobic 
cleft can accommodate the structurally analogous APOEα 4 and PLIN3α 5 helical regions. Mirroring 
DENV C-LDs interaction (previously shown experimentally to require PLIN3), we experimentally 
demonstrated that DENV C-VLDL interaction requires APOE. Thus, the results fit well with previous 
data and suggest future drug development strategies targeting the above mentioned α -helical 
structures.
Dengue virus (DENV) causes a mosquito-borne disease that leads to over half a million hospitalizations 
and 20,000 deaths worldwide every year1–4. A recent estimative puts the global toll in 390 million people 
infected per year5, roughly three times higher than earlier projections1,3,4,6. The infection by DENV can 
have several clinical manifestations, ranging from essentially asymptomatic to the well-known dengue 
hemorrhagic fever and the often fatal dengue shock syndrome1,3–8. Importantly, epidemiological data 
suggest that people who have been previously exposed to one of the four dengue virus serotypes are, 
in a subsequent infection by another serotype, at a greater risk of developing more severe forms of 
the disease, including the often fatal hemorrhagic fever9. DENV serotypes are now spreading further 
due to the globalization of trade and travel, increasing the range and frequency of dengue epidem-
ics1,5,10–17. Furthermore, globalization and climate changes have also fuelled the geographical expansion 
of the dengue mosquito vectors, Aedes albopictus and Aedes aegypti2,5,10–12,18,19. Their area of distribution 
now includes not only tropical and subtropical regions of the planet, but also temperate areas in USA12 
and Europe11,19, where three local outbreaks of the disease have occurred since 201013–17. Importantly, 
even in temperate climates, Aedes spp. mosquitoes eradication attempts have been largely unsuccess-
ful2,19. Dengue is the world’s fastest-growing tropical disease, for which there are no effective and specific 
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treatments or commercial vaccines1,20, partially due to the lack of knowledge on basic aspects of the viral 
life cycle21. The development of an effective drug or therapy against dengue is thus a major priority.
For this purpose key insights can be gained from comparing DENV with other closely related viruses. 
DENV belongs to the Flavivirus genus and Flaviviridae family21, a taxon that includes other major 
human pathogens, such as the yellow fever virus, West Nile virus and hepatitis C virus, among oth-
ers21,22. These viruses share common life cycle features and similar virion structure21, with homologous 
proteins presenting highly conserved regions21,23,24. The viral particle is relatively simple: a lipid bilayer, 
where the envelope and membrane proteins are located, surrounds a nucleocapsid where a positive sense 
single-stranded genomic RNA forms a complex with multiple copies of the capsid (C) protein25. In 
addition to these three structural proteins, DENV presents seven non-structural proteins21. Despite their 
name, structural proteins possess a number of other roles in the virus life cycle. DENV C is an 100 amino 
acid residues homodimeric protein, containing four α -helical regions and an intrinsically disordered 
N-terminal domain23,26,27 (see Supplementary Fig. S1A online). This protein is a potential drug target 
against DENV infection28 due to its interaction with host intracellular lipid droplets (LDs), essential for 
viral replication29, and with very low-density lipoproteins (VLDL)23,30,31, through which it may prompt 
the formation of lipoviroparticles31 (described below).
We have previously studied DENV C-LDs interaction using different biophysical techniques and viral 
replication assays23,30. The data allowed us to show that DENV C binding to LDs is strong, specific, 
dependent on the high intracellular potassium concentrations and using perilipin 3 (PLIN3, also known 
as TIP4732) as the major ligand on LDs surface30. Secondly, we identified the DENV C amino acid res-
idues involved in this interaction23. This revealed that both the DENV C central hydrophobic α 2-α 2′ 
patch and a conserved N-terminal segment are involved in the binding to LDs23. These results allowed 
us to design pep14-23, a peptide based on part of the DENV C N-terminal domain and that acquires 
α -helical structure in the presence of negatively charged phospholipids33 being able to inhibit DENV 
C-LDs binding (an interaction required for viral replication), paving the way for new drug development 
approaches against dengue23,28,33.
We also studied DENV C interaction with human lipoproteins31, since the closely related hepatitis C 
virus can form highly infectious lipoviroparticles through the conjugation of the virion with host plasma 
lipoproteins34,35. We found that DENV C interacts strongly and specifically with VLDL, but not with low 
density lipoproteins (LDL)31. A major difference between these two plasma lipoproteins is that apolipo-
protein E (APOE) is typically found in the VLDL surface, while it is almost totally absent in LDL36,37. 
Strikingly, APOE is an α -helical protein38 that is structurally similar to the LDs surface protein PLIN339. 
This parallel, together with the absence in LDL, hints that APOE may be the DENV C molecular target 
on VLDL surface31. Supporting this hypothesis, the DENV C-VLDL interaction also requires potassium 
ions as in the case of DENV C-LDs binding and, most importantly, it is also inhibited by pep14-23, 
suggesting a common mode of action31.
Here, taking all the above into account, we aimed at evaluating if DENV C interaction with LDs and 
VLDL may involve specific and similar sequences/structures of, respectively, PLIN3 and APOE. Our 
data support the hypothesis, suggesting also that the DENV C hydrophobic cleft can accommodate the 
structurally similar APOE α -helix 4 and PLIN3 α -helix 5 regions in a direct interaction with DENV 
C α -helices 1 and 2, fitting well with previous data23,30,31 and suggesting future avenues of research by 
targeting the helical structures proposed to be involved in these interactions.
Results
We originally demonstrated that DENV C is able to specifically bind VLDL, but not LDL31. This may be 
due to the differences in protein composition between VLDL and LDL. The former present APOE among 
their protein components, being essentially absent in LDL36,37. APOE may therefore be the molecular 
target of DENV C on the VLDL surface31. This is also supported by APOE structural similarity with 
PLIN338,39, which is found in the LDs surface, acting as ligand for DENV C30. As such, to investigate 
a possible role for APOE in the VLDL interaction with DENV C, the amino acid sequence of PLIN3 
proteins of both human (hPLIN3) and mouse (mPLIN3) were compared with the APOE sequences of 
human (hAPOE) and mouse (mAPOE). The comparison of the N-terminal region of APOE (first 220 
residues) with the C-terminal region of PLIN3 (last 220 residues) reveals several matching motifs of 
conserved regions Fig. 1A). These common sections of PLIN3 and APOE may thus be involved in similar 
protein-protein specific interactions, namely in the interaction with DENV C, especially if the structure 
of those sections is also conserved.
Therefore, to evaluate the structural relevance of the identical residues on PLIN3 and APOE, the 
three-dimensional lipid-free structures of hAPOE, mAPOE and mPLIN3 were superimposed (Fig. 1B–E). 
hAPOE and mAPOE structures co-localize well in space, especially regarding a stretch of 143 conserved 
residues that share a similar fold and display an average Cα root-mean-square deviation (RMSD) of 
2.73 Å (Fig. 1D). The comparison of both APOE structures with mPLIN3 also shows a strong similarity 
(Fig. 1B), especially in their four-helix-bundle motif (Fig. 1C), as noticed by other authors39.
In addition to the resemblance between hAPOE and mAPOE, as well as their overall structural sim-
ilarity to mPLIN3, some key insights can be gained from more closely looking at mPLIN3 and hAPOE 
structural superposition. In particular, hAPOEα 4 (see Supplementary Fig. S1B online) includes the func-
tionally relevant LDL receptor (LDLR)-binding region38,40–43 (Fig. 1A) and superimposes particularly well 
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with mPLIN3α 5 (see Supplementary Fig. S1C online). In fact, mPLIN3α 5 and hAPOEα 4 are the only 
sections of these proteins that are conserved in terms of amino acid sequence (Fig.  1A) and that also 
co-localize well in space (Fig. 1E), with a considerably low average Cα RMSD of 2.05 Å for a 23 residues 
long superimposing region. This compares very well with the 2.72 Å Cα RMSD of the corresponding 23 
amino acids homologous regions of mouse and human APOE protein structures.
Figure 1. Sequence and structure similarity between apolipoprotein E and perilipin 3. (A) Conserved 
amino acid residues between APOE N-terminal and PLIN3 C-terminal regions. Red stands for strictly 
conserved residues and black for stereochemically and/or functionally identical residues. In the APOE-
PLIN3 consensus line, “h”, “+ ”, “–” and “Z” stand respectively for hydrophobic, cationic, anionic and E or 
Q (glutamate or glutamine)63. The consensus includes the APOE α 4 region (between residues T130 and 
A160), corresponding to the APOE LDLR-binding region38,40–43. (B) APOE α -helix 4 (APOEα 4) and PLIN3 
α -helix 5 (PLIN3α 5) present highly similar structures, as shown by superimposing the tridimensional 
lipid-free structures of the full length hAPOE (red) and the mAPOE N-terminus (green) with the mPLIN3 
C-terminus (blue). (C) APOE superimposition with PLIN3 structures occurs mostly via their common and 
extremely similar four-helix-bundle motif, as previously reported39. (D) Amino acid residues conserved 
between APOE and PLIN3 are highlighted according to the same color scheme as in (B) but with the 
non-conserved residues colored gray. APOEα 4 and PLIN3α 5 align particularly well in terms of sequence 
and structure. (E) Superimposition of hAPOE, mAPOE and mPLIN3 structures highlighting the residues 
conserved both in terms of sequence and structure (the color scheme is as described in B but showing 
in gray all other residues). These residues are exclusively located in the APOEα 4 and in the PLIN3α 5 
superimposing helices. The Cα RMSD of hAPOEα 4 and mAPOEα 4 compared against mPLIN3α 5 are 
2.05 Å and 2.72 Å, respectively, within the same degree of variation of hAPOE and mAPOE α 4 helices 
(average Cα RMSD of 2.14 Å). Taking into account the previously documented DENV C binding to VLDL31 
and LDs23,29,30, the strong resemblance between APOEα 4 and PLIN3α 5 suggests that these highly similar 
α -helical regions may act as DENV C molecular targets on VLDL and LDs, respectively.
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It could be argued that the APOEα 4/PLIN3α 5 structural similarity could be due to both being within 
a roughly equally-sized α -helix. However, in addition to the structure similarity, similar amino acid 
sequences were also found. To evaluate the significance of this motif similarity, the frequency and iden-
tity of the proteins where this motif could be naturally found was determined. Additionally, the like-
lihood of the motif to occur by chance was tested by using a non-uniform Bernoulli model in a large 
random database44 while searching their consensus sequence motifs via the ScanProsite web server from 
ExPASy45 (Table  1). Taking the generic AP1 motif identified in Table  1 ([ALVIM]-X-[STCNQDEH]-
[STCNQDEH]-[ALVIM]-[RK]-X(10)-[STCNQDEH]-D-L-Q-X(2)-[ALVIMFYW]) and searching for it in 
the UniProtKB/Swiss-Prot database, 40 matching protein sequences were identified, while only 11 would 
be likely to appear by random chance. From these 40 sequences, 25 are either PLIN3 or APOE sequences. 
Slightly restricting this motif to the AP2 motif of Table 1 ([ALVIMFYW]-X-[ST]-[NH]-[ALVIMFYW]-
[RK]-X(10)-[NQDE]-D-L-Q-X(2)-[ALVIMFYW]), all protein hits that are neither APOE nor PLIN3 
are excluded. Most importantly, all the 25 APOE and PLIN3 hits are kept, while only 1 hit would be 
expected to occur by chance. Further restricting the motif from AP3 to AP8 sequence motif (our original 
consensus motif generated from the alignment described in Fig. 1A), not only all random occurrences 
are removed, but most APOE and PLIN3 hits are also preserved (22 out of the 25 initially found). This 
APOEα 4 alignment with PLIN3α 5 is thus remarkable within the overall sequence and structure, since 
it even includes similar orientations of the amino acid side chains. Given the high APOEα 4/PLIN3α 5 
similarity and the previously documented DENV C binding to VLDL31 and LDs23,29,30, APOEα 4 and 
PLIN3α 5 may be the DENV C specific targets in VLDL and LDs, respectively.
Assuming APOEα 4 and PLIN3α 5 as the DENV C-binding domains, this implies that further stud-
ying their sequences and structures (especially regarding the similarities they may possess) may reveal 
important aspects of their mode of action, including their possible interaction mechanism with DENV C. 
Given the interest in APOEα 4 function and the wealth of information on APOE complete protein struc-
ture (see Supplementary Fig. S2A online), the currently known role of APOEα 4 was analyzed within the 
context of the overall APOE structure (see Supplementary Fig. S2 online)38. Some major points should 
be taken into consideration. First of all, APOEα 4 is physiologically relevant for protein-protein interac-
tions since it is responsible for APOE binding to LDLR40,41,43. Secondly, not only APOEα 4 and PLIN3α 5 
are strikingly similar (Fig. 1), but also APOE and PLIN3 localize at the surface of their respective lipid 
systems (VLDL and LDs)38,46. Third, these two lipid systems are extremely alike in terms of composition 
and structure36,37,46,47. As such, the conserved regions of these proteins may adopt similar conformations 
when located in their natural lipid systems. Studying APOE structure may thus give important clues on 
the understanding of APOEα 4 and PLIN3α 5 biological functions.
APOE experimental structural data (see Supplementary Fig. S2 online) reveals that APOEα 4 interacts 
directly with APOE α -helical N-terminal region (APOEα N, residues K1-S44, identified in Supplementary 
Fig. S2B online)38. Importantly, APOE structure should not be considered static, as within the lipoprotein 
physicochemical environment the four-helix-bundle may adopt an open structure (see Supplementary 
Fig. S2C online)38. In either case, APOEα 4 remains quite close to APOEα N (see Supplementary Fig. 
S2D online) when it is within lipoproteins (see Supplementary Fig. S2C online)38. Thus, the APOEα N 
section, containing APOE N-terminal α -helices α N2 (hAPOEα N2) and α 1 (hAPOEα 1), is relevant 
for hAPOEα 4 function and deserves a closer inspection (see Supplementary Fig. S1B online for details 
regarding the nomenclature of hAPOE secondary structure elements).
hAPOEα N sequence and structure are shown in Fig. 2, highlighting in orange the amino acid residues 
that are within 5 Å of hAPOEα 4 (the hAPOE domain structurally analogous to mPLIN3α 5; Fig.  1F). 
In the same figure, hAPOEα 4 residues conserved in terms of sequence between APOE and PLIN3 are 

















AP1 [ALVIM]-X-[STCNQDEH]-[STCNQDEH]-[ALVIM]-[RK]-X(10)- [STCNQDEH]-D-L-Q-X(2)-[ALVIMFYW] 40 16 6 18 2.1 11
AP2 [ALVIMFYW]-X-[ST]-[NH]-[ALVIMFYW]-[RK]-X(10)-[NQDE]- D-L-Q-X(2)-[ALVIMFYW] 25 19 6 0 0.12 1
AP3 [ALVIM]-X-[ST]-[NH]-[ALVIM]-[RK]-X(10)-[NQDE]-D-L-Q-X(2)-[ALVIMFYW] 22 16 6 0 0.073 0
AP4 [ALVIM]-X-[ST]-[NH]-[ALVIM]-[RK]-X(10)-[NDE]-D-L-Q-X(2)-[ALVIMFYW] 22 16 6 0 0.058 0
AP5 L-X-[ST]-[NH]-[ALVIM]-[RK]-X(10)-[NDE]-D-L-Q-X(2)- [ALVIMFYW] 22 16 6 0 0.017 0
AP6 L-X-[ST]-[NH]-[LVI]-[RK]-X(10)-[NDE]-D-L-Q-X(2)-[ALVIMFYW] 22 16 6 0 0.012 0
AP7 L-X-[ST]-[NH]-[LVI]-[RK]-X(10)-[NDE]-D-L-Q-X(2)-[LF] 22 16 6 0 0.0040 0
AP8 L-X-[ST]-[NH]-[LV]-[RK]-X(10)-[NDE]-D-L-Q-X(2)-[LF] 22 16 6 0 0.0029 0
Table 1.  Validation of APOE α -helix 4 and PLIN3 α -helix 5 sequence consensus.
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highlighted in red (Fig. 2B–D). By observing them more closely, it becomes clear that hAPOEα N and 
hAPOEα 4 interact with each other even when hAPOE is within the lipoprotein, as previously reported38. 
Other proteins, such as the LDLR protein family, bind to hAPOEα 438,40–43. APOEα 4 has therefore the 
crucial ability to mediate protein-protein interactions. Looking at the APOEα N and APOEα 4 closely 
packed structure (Fig.  2B–D and Supplementary Fig. S2, online), it is expectable that proteins which 
interact with the APOEα 4 region may adopt a conformation similar to APOEα N (Fig. 2E–G).
Considering that (i) DENV C interacts with APOE-containing VLDL31 and with LDs via PLIN330, 
(ii) PLIN3 and APOE are extremely similar39, (iii) mPLIN3α 5 is extremely similar to hAPOEα 4, (iv) 
hAPOEα 4 is functionally relevant for protein-protein interactions, and (v) hAPOEα N interacts directly 
with hAPOEα 4, we hypothesize that the proposed hAPOE-DENV C interaction31 may occur via 
hAPOEα 4 binding to the DENV C domain structured similarly to hAPOEα N. Thus, DENV C and 
hAPOEα N structures were compared in detail (Fig.  3). As shown in Fig.  3A, the hAPOE N-terminal 
α -helices N2 (hAPOEα N2) and 1 (hAPOEα 1) superimpose perfectly with DENV C α -helices 1 and 2, 
respectively, with an overall average Cα RMSD of 1.68 Å for a 20 amino acid residues long superposi-
tion (please consult Supplementary Fig. S1 online for hAPOE motifs nomenclature). Therefore, DENV 
C α -helices 1 and 2 mimic the conformation of hAPOEα N. Moreover, looking at the sequence align-
ment of these APOE and DENV C domains (Fig. 3B) within the context of the structural superposition 
(Fig. 3A), we observe that several functionally relevant residues are in similar positions of the sequences 
(Fig.  3B,C). This alignment is prominent at DENV C α 2 (from residues K45 to L57) and APOEα 1 
(from R25 to L37), yielding a 13 amino acid residues consensus: “+ hXhALXXFhXYL” (“h” and “+ ” 
stand, respectively, for hydrophobic and cationic residues). The same stretch of similar residues is cru-
cial for DENV C interaction with LDs via the surface protein PLIN323,29,30. Remarkably, this sequence 
and backbone structure superposition of APOEα N2 and APOEα 1 with DENV C helices α 1 and α 2, 
respectively, is also extended to the side chains of specific amino acid residues of both proteins (Fig. 3C). 
Figure 2. hAPOE α -helical N-terminal region interacts with hAPOEα 4 through conserved residues. 
(A) Sequence of hAPOE α -helical N-terminal region (hAPOEα N, residues K1 to S44), which interacts with 
hAPOEα 438. Highlighted in orange are the hAPOEα N residues that are within 5 Å of hAPOEα 4 (which 
is similar to PLIN3α 5, as shown in Fig. 1F). (B–D) Different ribbon views of hAPOEα N and hAPOEα 4. 
In these views, hAPOEα N residues within 5 Å of hAPOEα 4 are colored in orange and hAPOEα 4 residues 
conserved between hAPOEα 4 and mPLIN3α 5 are colored in red. (E–G) hAPOEα N ribbon views, showing 
the side chains of the residues within 5 Å of hAPOEα 4 colored in orange. Proteins that interact with the 
hAPOEα 4 region may do so via a conformational arrangement similar to hAPOEα N structure.
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Most importantly, the DENV C α 2 residues that superimpose both in the backbone and side-chains are 
involved in the interaction with lipid droplets23 via PLIN330. Thus, overall, the hAPOEα N residues that 
bind hAPOEα 4 are very similar to functionally relevant DENV C residues, displaying comparable back-
bone and side-chain structural orientation and sequence (Fig. 4).
To determine the likelihood of a random simultaneous occurrence of the 13 amino acid residues 
motif [RK]-[LMW]-X-[LM]-A-[FL]-X(2)-F-[LFW]-[DRK]-[FVY]-L (named AF8 in Table 2) present in 
APOE and DENV C, the ExPASy ScanProsite web server45 was employed to evaluate the frequency of 
such a motif in the UniProtKB/Swiss-Prot protein database (Table 2). Interestingly, this motif is highly 
conserved among dengue virus capsid proteins and primate APOE proteins, supporting a common role 
of these regions of APOE and DENV C. It is also not a random occurrence, since 26 APOE and DENV C 
conserved sequences appear where none is expected to occur just by chance. Importantly, this is a region 
identified as essential for DENV C interactions with LDs23,29, being conserved among the four dengue 
virus serotypes48,49. Given the previously reported sequence homology between the capsid proteins of 
other mosquito-borne Flavivirus23, the more generic motifs common to APOE and DENV C proteins, 
such as the AF6 motif, were also studied by searching them in the database (Table  2). As expected, 
Figure 3. hAPOEα N structure superimposes with DENV C α -helices α 1 and α 2 backbone and side 
chains. (A) DENV C structure (gray) superimposed with hAPOEα N α -helices (orange), showing that 
hAPOEα N2 and hAPOEα 1 α -helices superimpose well with the backbone structure of DENV C α 1 and 
α 2 helices. (B) Looking at these α -helices sequence alignment and taking into account the structural 
superposition, it can be noticed that several functionally relevant amino acid residues are in similar positions 
of the sequences, namely the region “ +hXhALXXFhXYL” (DENV C α 2 and hAPOEα 1). (C) A closer 
inspection of the side chains orientation of the functionally relevant amino acid residues of both proteins 
shows that their side chain structures also superimpose. Additionally, the side chains of functionally relevant 
residues of hAPOEα N38 and DENV C23 display a similar spatial orientation.
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when searching for a more generic and less restrictive motif, other protein sequences were found besides 
APOE and DENV C proteins. Interestingly, several of these were C protein sequences of other Flavivirus. 
Remarkably, 33 sequences were found to contain the AF6 motif (comprising 4 APOE protein hits, and 
22 capsid proteins from DENV strains and 7 other Flavivirus). According to the statistical algorithm, the 
likelihood of this being a random protein hit occurrence in the database is null. Making the motif more 
generic (sequences AF5 to AF1 of Table 2) does not increase substantially the number of random hits of 
proteins that are neither APOE nor Flavivirus capsid proteins. The most generic motifs tested, AF1 and 
AF2, generate 61 and 42 hits, respectively. Although these are very generic motifs, the majority of the 
hits (33 hits) are still from APOE or flaviviruses C proteins. Overall, the appearance of other flaviviruses 
C proteins in the UniProtKB/Swiss-Prot search (Table  2) supports a generic role for these APOE-like 
motifs across related viruses. Most importantly, together with the statistical analysis performed, this also 
demonstrates that the structural and sequence similarities between APOE and DENV C described pre-
viously are likely to be functionally relevant and deserve to be investigated in detail. Most importantly, 
the data gathered clearly suggest APOE as being the molecular target of DENV C on the VLDL surface.
As such, following previously established procedures23,30,31,50, atomic force microscopy (AFM)-based 
force spectroscopy studies were employed to determine the role of APOE on DENV C-VLDL binding. 
Briefly, tapping on VLDL with AFM tips where DENV C was covalently attached allowed measuring 
the frequency (or probability) of DENV C-VLDL (un)binding events, as well as the respective binding 
force, in the presence and in the absence of a specific anti-APOE antibody, as schematized in Fig. 5A. 
The resulting rupture force histograms depict a substantial reduction of the strong and specific inter-
actions between DENV C and VLDL in the presence of the anti-APOE antibody at 100 μ g/L or 1 μ g/L 
(Fig. 5B). Such a reduction of the frequency of DENV C-VLDL (un)binding events is not observed in the 
presence of either 100 μ g/L or 1 μ g/L of an isotype-matched antibody not specific for APOE. Comparing 
DENV C binding to VLDL in the absence of antibodies and in the presence of the lowest concentration 
tested (1 μ g/L of the anti-APOE specific antibody) shows that the presence of the antibody causes a 
46.9% inhibition of DENV C-VLDL binding (defined as the reduction of the frequency or probability of 
binding events; Fig. 5C). At 100 μ g/L of anti-APOE antibody, a 52.2% inhibition was observed. Control 
experiments with VLDL incubated with 1 μ g/L or 100 μ g/L of the isotype-matched antibody yielded only 
a 6.6% or 9.1% reduction of the frequency of (un)binding events, respectively (Fig.  5C). The effect of 
anti-APOE on the reduction of the specific (un)binding events becomes even clearer if one takes into 
consideration a force threshold at 25 pN, considering as specific binding events those above this value. In 
Figure 4. DENV C hydrophobic cleft can accommodate the structurally analogous hAPOEα 4 and 
mPLIN3α 5 α -helical regions. (A) DENV C (gray) hydrophobic cleft (formed by the α 1-α 2-α 2′ -α 1′ 
regions) is involved in the interaction with LDs23 and is suggested to also play a role in DENV C interaction 
with VLDL31. As shown in Fig. 3, DENV C α 1 and α 2 helices fit structurally with the hAPOEα N helices 
(orange). If hAPOEα 4 (red) is displayed as when interacting with hAPOEα N38, it is clear that the entire 
APOEα 4 α -helical region fits in the DENV C hydrophobic pocket. (B) Structurally aligning onto the 
previous figure the PLIN3α 5 (blue) structure (which superimposes with APOEα 4, as depicted in Fig. 1) 
shows that PLIN3α 5 also fits the same pocket of DENV C structure. The DENV C residues involved in 
PLIN3-mediated DENV C interaction with LDs23,30 are colored in yellow, showing that they would clearly 
be affected if PLIN3 binds to DENV C via the hydrophobic pocket, as proposed. Overall, this fits well with 
previous data showing DENV C interaction with LDs23,29,30 and VLDL31.
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this region of stronger and specific forces30,31, the percentage of inhibition by 1 μ g/L anti-APOE is 75.2% 
(Fig. 5B). The weak interactions remaining after anti-APOE treatment are essentially related to unspecific 
binding events. In the absence of the antibodies, the force necessary to break the DENV C-VLDL binding 
is 29.7 ± 0.4 pN and 52.1 ± 4.4 pN (values are mean ± s.e.m.), respectively for the 1st and 2nd Gaussian 
peaks of the histogram. In the presence of anti-APOE, a weaker peak emerges at approximately 20 pN. 
This weaker force is typical of unspecific weak binding events, as observed in previous studies of DENV 
C binding to LDs30 and VLDL31. These results further demonstrate that APOE is the molecular target of 
DENV C on the VLDL surface, as discussed ahead.
Discussion
Taking all of the above into account, given that APOEα N binds specifically to APOEα 438, it is thus 
anticipated that DENV C, namely through its α 1 and α 2 helices (structurally analogous to APOEα N), 
is able to perform a similar function, binding to APOEα 4. This would explain its documented ability to 
bind VLDL (rich in APOE) but not to LDL31. With this in mind, the overall meaning of the sequence 
and structure similarities between APOE, PLIN3 and DENV C proteins were further investigated. As 
shown in Fig.  4, APOE and DENV C structures were compared taking into account APOEα N ability 
to interact with APOEα 4 (Fig. 2A and Supplementary Fig. 2 online) and APOEα N similarity to DENV 
C α 1 and α 2 helices (Fig.  3). Briefly, first the structures of APOEα N with DENV C were aligned as 
described in Fig. 3. Next, these aligned structures were superimposed with the complete APOE structure. 
For clarity, only the APOEα 4 helix is then displayed (as described in Fig. 2). A perfect fit of APOEα 4 
into the DENV C hydrophobic cleft is immediately observed, as shown in Fig. 4A. Finally, as described 
for Fig. 1, PLIN3 is then superimposed onto APOE. The final image is shown in Fig. 4B, showing that 
PLIN3α 5 also fits within the DENV C α 1-α 2-α 2′ -α 1′ pocket. Therefore, from Fig.  4 it is clear that 
DENV C hydrophobic α 1-α 2-α 2′ -α 1′ pocket (i.e., formed by its α 2-α 2′ interface and the α 1 and α 1′ 
structural domains) can accommodate APOEα 4 and PLIN3α 5 α -helical regions. To stress the relevance 
of these matches, in Fig.  4B we also highlighted in yellow the side chains of the residues of DENV C 
reported to be affected by the interaction with LDs23. In such an arrangement, the LDs surface protein 
PLIN3 would be able to interact with DENV C relevant residues via its PLIN3α 5 α -helix, fitting well 
with previous experimental information23,30.
The data presented here indicate that PLIN3α 5, as well as APOEα 4, can interact with the α 2 and α 1 
domains of DENV C (Fig.  4). This agrees well with the documented DENV C direct interaction with 
LDs23,30, which involves residues of those α -helices (as well as N-terminal residues23) and the LDs sur-
face protein PLIN330. Interestingly, the functionally relevant APOEα 4 region38,40–43 is similar in structure 
and sequence to PLIN3α 5 (Fig.  1), while APOEα N and DENV C α 1-α 2 are perfectly superimposing 
structures (Fig.  3). APOEα 4 and PLIN3α 5 fill the three-dimensional hydrophobic pocket of DENV C 
in such an elegant manner that conserved DENV C residues fundamental to DENV C-LDs interaction23 
would be able to promote that binding (Fig. 4).
The results presented here point to APOE as the main protein ligand of DENV C on the VLDL surface 
(Fig. 5). The inhibitory effect of an anti-APOE antibody on DENV C-VLDL interaction is demonstrated 
by single-molecule AFM-based force spectroscopy data. A decrease on the binding force and on its prob-
ability to occur is observed in the presence of the antibody. The effect of anti-APOE on the reduction 
of the specific (un)binding events becomes even clearer if one takes into consideration a force threshold 
at 25 pN, considering as unspecific binding events those below this value. In this region of stronger and 
specific forces30,31, the percentage of inhibition is 75.2% (Fig. 5B). Almost only unspecific weak binding 
events remain on anti-APOE treated VLDL. Importantly, DENV C-VLDL interaction is just slightly 
affected by the presence of an isotype-matched antibody (Fig. 5C). All this clearly supports APOE as the 




















AF1 [RK]-[ALVIMFYW]-X-[LM]-A-[ALVIMFYW]-X(2)-F-[ALVIMFYW]-[STCNQDEHRK]-[FVY]-X 61 4 22 7 28 8.6 47
AF2 [RK]-[ALVIMFYW]-X-[LM]-A-[ALVIMFYW]-X(2)-F-[LFW]-[STCN-QDEHRK]-[FVY]-X 42 4 22 7 9 3.2 17
AF3 [RK]-[FLIVMW]-X-[LM]-A-[FLIVM]-X(2)-F-[LFW]-[STCNQ-DEHRK]-[FVY]-X 36 4 22 7 3 1.6 9
AF4 [RK]-[FLIVMW]-X-[LM]-A-[FLIVM]-X(2)-F-[LFW]-[DERK]-[FVY]-X 34 4 22 7 1 0.76 4
AF5 [RK]-[FLIVMW]-X-[LM]-A-[FLIVM]-X(2)-F-[LFW]-[DRK]-[FVY]-X 34 4 22 7 1 0.55 3
AF6 [RK]-[FLIVMW]-X-[LM]-A-[FLIVM]-X(2)-F-[LFW]-[DRK]-[FVY]-[LT] 33 4 22 7 0 0.084 0
AF7 [RK]-[FLIVMW]-X-[LM]-A-[FLIVM]-X(2)-F-[LFW]-[DRK]-[FVY]-L 26 4 22 0 0 0.053 0
AF8 [RK]-[LMW]-X-[LM]-A-[FL]-X(2)-F-[LFW]-[DRK]-[FVY]-L 26 4 22 0 0 0.011 0
Table 2.  Validation of APOE α -helix N2 and Flavivirus C proteins α -helix 2 sequence consensus.
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Figure 5. DENV C protein binds specifically to APOE on VLDL. (A) Schematic representation of the 
AFM-based force spectroscopy inhibition assay. DENV C, covalently attached to the AFM tip, binds 
to VLDL adhered to the mica surface, in buffer, in the absence of the anti-APOE antibody (left panel); 
however, DENV C-VLDL interactions are inhibited by the presence of anti-APOE (right panel). Binding 
events are measured through the change on the deflection of the AFM cantilever, which is detected by 
a laser pointed on the backside of the cantilever and reflected on a photodetector. (B) Force-rupture 
histograms for the DENV C-functionalized AFM tips interacting with VLDL in the absence (red) or 
presence (green) of 1 μ g/L anti-APOE antibody. (C) According to the percentage of (un)binding events, the 
percentage of inhibition of the DENV C-VLDL binding in the presence of anti-APOE antibody is 46.9% 
at 1 μ g/L and 52.2% at 100 μ g/L (green bars). Controls were performed with the same concentrations of an 
isotype-matched antibody, yielding a percentage of inhibition of just 6.6% and 9.1%, respectively (gray bars). 
Looking solely on the stronger interaction forces typical of specific binding events (>25 pN), the effect of 
anti-APOE at 1 μ g/L becomes even clearer, with 75.2% DENV C-VLDL binding inhibition. All experiments 
(and respective controls) were performed in triplicate with the same acquisition settings, leading to 
approximately 5000 single rupture-force measurements for each histogram.
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VLDL surface ligand of DENV C. It could be reasoned that, as APOE can also be found in LDL (although 
to a quite lesser extent than on VLDL)51–53, it could also allow for DENV C-LDL binding. However, this 
does not occur, as determined experimentally31. The percentage of LDL particles that contain APOE is 
below 4.4%54–57. As such, when using single-molecule AFM-based force spectroscopy to study how a sin-
gle DENV C molecule interacts with an LDL particle, there is a <5% chance of encountering an LDL par-
ticle containing APOE. Even for those particles that do have APOE, stochastically, a binding event would 
be established only with a subfraction of them. As a result, no statistically significant binding would be 
expectable. This is indeed what we previously observed experimentally for DENV C binding to LDL31.
To conclude, the similarities between DENV C interaction with LDs and VLDL are striking. All these 
interactions require potassium ions30,31 and, as demonstrated here, the PLIN3-mediated LDs and the 
APOE-mediated VLDL interaction with DENV C are also considerably similar in terms of functionally 
relevant structures and amino acid sequences. Overall, we propose that DENV C-VLDL binding involves 
APOEα 4 residues in a similar way as DENV C-LDs interaction requires PLIN3α 5 residues. This explains 
how DENV C binding to VLDL can be inhibited by pep14-2331, a peptide originally designed to prevent 
the PLIN3-mediated DENV C interaction with LDs23,28. Noteworthy, an APOE-derived peptide corre-
sponding to the APOEα 4 region highlighted here was also found to inhibit viral entry of the closely 
related hepatitis C virus58. Importantly, the general concept of viral proteins mimicking host protein 
structures for interactions has also been observed before for other viruses, for example with influenza 
NS1 acting as histone mimic for hPAF1C (human PAF1 transcription elongation complex) interaction59. 
These findings also suggest future avenues of research aiming at simultaneously targeting DENV C inter-
actions with VLDL and LDs by focusing on the inhibition of these specific protein-protein interactions 
via rational drug design. The inhibition of these interactions would also be a good tool to study the 
potential biological relevance of APOE for the dengue virus life cycle. Finally, given the occurrence of 
APOE-like motifs in several other flaviviruses capsid proteins, as reported here, this approach may thus 
be of potential use to target closely related viruses such as Japanese encephalitis virus, St. Louis enceph-
alitis virus, Murray valley encephalitis virus, Kunjin virus and West Nile virus.
Methods
Sequence alignment and consensus regions between apolipoprotein E and perilipin 3. Protein 
sequences were obtained from the National Center for Biotechnology Information Protein database 
(www.ncbi.nlm.nih.gov/protein/) with the reference numbers stated ahead in parenthesis. Human (Homo 
sapiens) and mouse (Mus musculus) proteins are identified by the prefixes “h” and “m”, respectively. In 
apolipoproteins E (hAPOE, NP_000032.1; mAPOE, NP_033826.2), we discarded the initial 18 amino 
acids of each sequence, which correspond to the transmembrane signal peptide that is cleaved after 
translation within the endoplasmic reticulum (according to the NCBI information retrieved from the 
SignalP 4.0 algorithm60). We compared the N-terminal APOE proteins (residues 1 to 220) that align 
with C-terminal regions of human (hPLIN3, NP_005808.3, residues 215 to 434) and mouse (mPLIN3, 
NP_080112.1, residues 218 to 437) perilipin 3 (PLIN3) proteins by performing a multiple sequence align-
ment using Clustal W2 (www.ebi.ac.uk/Tools/msa/clustalw2/)61,62. Next, the consensus was created with 
equal or stereochemically similar amino acid residues in the same aligned position. For stereochemically 
identical residues we used the symbol “h” for hydrophobic, “+ ” for cationic, “–” for anionic and “Z” for 
E or Q residues (according to the International Union for Pure and Applied Chemistry one-letter amino 
acid code63).
Structure comparison between APOE and PLIN3. Protein structures coordinates were extracted 
from the Protein Data Bank (PDB, www.pdb.org). All structures are from apoproteins (i.e., without 
bound non-protein components) and PDB identification codes are specified ahead after the protein 
name. APOE protein structures from human and mouse (hAPOE, 2L7B38; mAPOE, 1YA964) were used 
in the analysis. The 2L7B PDB file structure of hAPOE was obtained from nuclear magnetic resonance 
(NMR) data38. It was selected out of 14 hAPOE available structures since it is currently the most com-
plete structure available, obtained from the full length protein38. This PDB file contains 20 model struc-
tures of minimal energy that fit the experimental results, with little variation between each other (average 
Cα RMSD of 1.35 Å). Given this high resemblance between conformers, the first model (model 1) was 
chosen as the hAPOE reference structure, since it was also described by the authors as the best represent-
ative conformer in the ensemble38. 1YA9 is an X-ray structure of mAPOE (residues P4 to V177), and the 
only presently available64. Regarding PLIN3, the mouse protein X-ray structure (residues N206 to T430), 
with a single conformer (mPLIN3, 1SZI39) is presently the only PLIN3 structure available.
These three protein structures were superimposed through UCSF Chimera 1.6.2 software65 MatchMaker 
tool66. After that, we carefully analyzed the superposition visually. Then, using the Match-Align tool of 
UCSF Chimera66, which returns a sequence alignment based on the regions closer in space (less than 5 Å) 
and taking into account the structure superimposition, we identified the residues simultaneously similar 
in structure and sequence (e.g., revealing shared amino acid motifs at equivalent structural positions). 
Protein structure figures were obtained using UCSF Chimera 1.6.265. Structure alignments were comple-
mented by calculating the amino acid residues α -carbons root-mean-squared deviation (Cα RMSD) in 
the Swiss-PdbViewer 4.1 software67, using the equation 1:
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where x, y and z are the Cartesian coordinates of each atom in the aligned position, N is the number of 
atom pairs compared between structures 1 (reference) and 2, and i is the index of each atom in the set 
of comparison. To evaluate the degree of variation within the hAPOE structure that serves as a generic 
measure of the variability between the protein conformers, we averaged the Cα RMSD between model 
1 and the other 19 hAPOE models.
Structure and sequence comparison between DENV C and hAPOEαN. We compared the 
hAPOEα N (residues K1 to S44) structure from the 2L7B file (model 1) with the DENV serotype 2 
capsid protein structure (1R6R), previously obtained from NMR data27, which has 21 minimal energy 
models deposited in the PDB. Model 21, an energy-minimized average of several NMR conformers 
which serves as the best conformer to the data, was used as DENV C reference structure for the analy-
sis. DENV C and hAPOEα N comparison was performed via the MatchMaker tool66 of UCSF Chimera 
1.6.265. Then, we compared the amino acid sequence of the superimposing regions of both proteins via 
the Match-Align tool of UCSF Chimera66, with residue proximity of less than 5 Å. The sequence consen-
sus was constructed taking into account stereochemical similarities between amino acid residues aligned 
in the same position, as described above. RMSD values were calculated via Swiss-PdbViewer 4.167 and 
figures were constructed using UCSF Chimera 1.6.265.
Consensus motifs search. For the analysis of the consensus sequences of APOEα 4 and PLIN3α 5 
(Table 1), and of hAPOEα N and DENV C α 1-α 2 regions (Table 2), we used the ScanProsite web server 
from ExPASy (http://prosite.expasy.org/scanprosite45), scanning the motifs against the UniProtKB / 
Swiss-Prot protein sequence database (which contained 540,732 protein sequences deposited, including 
isoforms, when the analysis was performed). Motifs were based on the consensus sequences. PROSITE 
pattern syntax (http://prosite.expasy.org/scanprosite/scanprosite_doc.html#scanning_options) was used 
to describe both the motifs and the stereochemical similarities between amino acid residues. For each 
motif, we registered the number of hits from our proteins of interest (in different organisms), the number 
of results given and the expected number of random matches in a 100,000 protein sequences database. 
As the database used contained 540,732 protein sequences, we corrected accordingly (multiplying the 
given random match estimate by 5.41).
AFM-based force spectroscopy inhibition assay. To evaluate if the APOE at the surface of VLDL 
is involved on the binding to DENV C, we performed AFM-based force spectroscopy measurements of 
DENV C (VCPBio, Shenzhen, China) binding to VLDL (Kalen Biomedical LLC, Montgomery Village, 
MD, USA) in the presence or absence of a rabbit anti-human APOE antibody (Sigma, St. Louis, MO, 
USA), raised against a recombinant fragment corresponding to APOE amino acid residues 1 to 129. 
The effects of anti-APOE were evaluated by force spectroscopy after incubating the VLDL sample with 
the antibody at 100 μ g/L and 1 μ g/L, for 1 h at room temperature. All measurements were conducted in 
TEE-KCl buffer pH 7.4 (20 mM Tris-HCl, 100 mM KCl, 1 mM EDTA and 1 mM EGTA). Force spectros-
copy measurements were performed on a NanoWizard II atomic force microscope (JPK Instruments, 
Berlin, Germany), mounted on an Axiovert 200 inverted optical microscope (Zeiss, Jena, Germany), 
using DENV C functionalized OMCL TR-400-type silicon nitride AFM tips (Olympus, Tokyo, Japan), 
as previously described30,31,68. The spring constant of the tips was calibrated by the thermal fluctuation 
method. The applied force was adjusted to 200 pN before retraction. Molecular recognition was searched 
by intermittently pressing the cantilevers on each VLDL, adsorbed on freshly cleaved muscovite mica. 
Data collection for each force-distance cycle was performed at 2 μ m/s, leading to a loading rate of 4 nN/s. 
Force curves were analyzed using the JPK image processing software v.4.2.61. For each experimental 
condition, approximately 5000 force-distance curves were collected, analyzed and adjusted by polynomial 
fit. Each experiment was performed at least three times, each time on different VLDL samples and with 
different functionalized tips. Histograms of the (un)binding forces of each data set were constructed 
choosing the ideal bin size to achieve the best fit (6 pN). Force rupture values below 10 pN were consid-
ered to represent noise, artifacts or unspecific interactions. From each histogram, the most likely single 
DENV C-VLDL binding rupture force was determined fitting the distributions of the rupture forces 
with the Gaussian model. The maximum values of the Gaussian peaks represent a single-molecule-based 
statistical measure of the force of the molecular bond. The anti-APOE antibody was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). As a negative control for the antibody-blocking experiments, the 
effect of the presence of an unspecific isotype-matched antibody (normal rabbit IgG serum; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was tested at 100 μ g/L and at 1 μ g/L, being incubated with VLDL 
for 20 minutes at room temperature prior to the AFM measurements.
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